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Background: Glioblastoma multiforme (GBM) is the most malignant type of glioma. Integrated classification based
on mRNA expression microarrays and whole–genome methylation subdivides GBM into five subtypes: Classical,
Mesenchymal, Neural, Proneural-CpG island methylator phenotype (G-CIMP) and Proneural-non G-CIMP. Biomarkers
that can be used to predict prognosis in each subtype have not been systematically investigated.
Methods: In the present study, we used Cox regression and risk-score analysis to construct respective prognostic
microRNA (miRNA) signatures in the five intrinsic subtypes of primary glioblastoma in The Cancer Genome Atlas
(TCGA) dataset.
Results: Patients who had high-risk scores had poor overall survival compared with patients who had low-risk
scores. The prognostic miRNA signature for the Mesenchymal subtype (four risky miRNAs: miR-373, miR-296,
miR-191, miR-602; one protective miRNA: miR-223) was further validated in an independent cohort containing 41
samples.
Conclusion: We report novel diagnostic tools for deeper prognostic sub-stratification in GBM intrinsic subtypes
based upon miRNA expression profiles and believe that such signature could lead to more individualized therapies
to improve survival rates and provide a potential platform for future studies on gene treatment for GBM.
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Glioblastoma multiforme (GBM) is the most lethal type of
glioma in adults due to its poor prognosis and resistance
to clinical therapy [1]. Despite the continuous improve-
ments in radiotherapy, chemotherapy, and surgical treat-
ments, the prognosis remains unsatisfactory [2]. Obstacles
result, in part, from the heterogeneous nature and variable
genetic aberrations among affected individuals. Develop-
ments of molecular biology offer a potential gene therapy
for GBM. With the deepening of the research, a growing
number of potential gene therapy targets have been identi-
fied, which calls for an urgent and objective classification
based on molecular signatures rather than the histopatho-
logic classification system [3]. Currently, many databases,
such as The Cancer Genome Atlas (TCGA) Research Net-
work, are being continuously improved and provide us
with a comprehensive catalogue of genomic information* Correspondence: yypl9@njmu.edu.cn
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stated.[4]. Several molecular-based classification systems, such as
mRNA expression-based and DNA methylation-based
systems, have identified abnormalities driving tumorigen-
esis and correlated clinical data of samples.
The generally accepted molecular classification divides
GBM into five subtypes: Proneural-G-CIMP, Proneural-
non G-CIMP, Neural, Classical and Mesenchymal. Each
subtype exhibits distinct biological behavior and charac-
teristic gene expression [5,6]. However, biomarkers,
which can be used to predict prognosis in each subtype,
have not been systematically investigated. In our study,
we identified significant miRNAs associated with clinical
outcomes in each subtype. The prognostic miRNA sig-
nature for the Mesenchymal subtype was validated in an
independent cohort containing 41 samples. The findings
reveal the potential prognostic meaning of each subtype
and provide an alternative individual treatment for pa-
tients with GBM.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Datasets
The miRNA expression microarray data (Level 3) for GBM
samples were downloaded from The Cancer Genome Atlas
(TCGA) database (http://cancergenome.nih.gov). The cor-
responding clinical data with the molecular subtype anno-
tations were obtained from Ref [6]. In total, 448 primary
GBM cases with molecular annotations (120 cases of Clas-
sical subtype, 141 cases of Mesenchymal subtype, 73 cases
of Neural subtype, 29 cases Proneural-G-CIMP and 85
cases of Proneural-non G-CIMP) and miRNA expression
microarray data were included in our analysis. A total of
41 Mesenchymal primary GBM from the Chinese Glioma
Genome Atlas (CGGA) were used as a validation cohort
by qRT-PCR assay.
RNA isolation
Total RNA (tRNA) was extracted from frozen tissues
using the mirVana miRNA Isolation Kit (Ambion, Inc.,
Austin, Tex), and its concentration and quality were de-
termined with a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, Del) [7].
Real-time quantification of miRNAs by stem-loop RT-PCR
For the TaqMan-based real-time reverse transcription
polymerase chain reaction (RT-PCR) assays, an ABI
7300 HT Sequence Detection system (Applied Biosys-
tems, Foster City, CA) was used. All primers and probes
of hsa-miR-373, hsa-miR-296, hsa-miR-191, hsa-miR-
602 and hsa-miR-223, and RNU6B endogenous controls
for TaqMan miRNA assays were purchased from Ap-
plied Biosystems. Real-time PCR was performed as de-
scribed by Ref. [8]. The relative gene expression was
calculated via a 2−ΔΔCt method [9].
Statistical analysis
Based on the generally accepted molecular classification
of GBM (the classical, mesenchymal, neural, proneural-
G-CIMP and proneural-non G-CIMP subtypes), we first
analyzed the internal prognosis stratification of the five
subtypes based on the MGMT promoter methylator
phenotype. Kaplan-Meier survival analysis was used to
estimate the survival distributions. The log-rank test was
used to assess the statistical significance between the
stratified survival groups using GraphPad Prism 6.0 stat-
istical software. P < 0.05 was considered significant.
The expression level of each miRNA (n = 470) was
assessed by Cox regression analysis using the BRB array
tools package developed by Richard Simon and the
BRB-ArrayTools Development Team [10]. Permutation
Tests were performed with 10,000 permutations to se-
lect genes that were significantly associated with overall
survival. For the Classical subtype, seven miRNAs
with permutation P-values < 0.05 were selected as thecandidate genes; for Proneural-G-CIMP and Proneural-
non G-CIMP subtypes, three and ten miRNAs with
permutation P-values <0.05 were selected as candidate
genes. For Neural subtypes, eight miRNAs with permu-
tation P-values < 0.015 were selected as candidate genes,
and for Mesenchymal subtypes, five miRNAs with permu-
tation P-values < 0.01 were selected as candidate genes.
The significant miRNAs were divided into risky and pro-
tective types. Risky miRNAs were defined as miRNAs with
a hazard ratio for death greater than 1. In contrast, pro-
tective miRNAs were defined based on a hazard ratio for
death less than 1.
Using these significant miRNAs, a risk-score formula
for predicting survival was developed based on a linear
combination of the gene expression level (expr) weighted
by the regression coefficient derived from the univariate
Cox regression analysis (β) [11,12]. The risk score for
each patient was calculated as follows:
Risk score ¼ exprgene1  βgene1 þ exprgene2  βgene2
þ exprgene3  βgene3 þ…exprgene n
 βgene n
For each subtype, patients were divided into high-risk
and low-risk groups according to the cutoff value (me-
dian risk score); patients in high-risk group are expected
to have a poor outcome. The Kaplan-Meier method
was used to estimate overall survival time for the two
groups. Differences in survival times were analyzed using
the two-sided log rank test. The significant miRNAs
remained the same in validation set.
SPSS 13.0 for Windows (SPSS, Inc., Chicago, Ill) was
used to conduct survival analyses. All tests were 2-tailed,
and the significance level was set at P <0 .05.
Results
Identification prognostic microRNA signatures in the five
molecular subtypes of primary glioblastoma
In classical subtype GBM, seven miRNAs (five risky
miRNAs: hsa-miR-26a, hsa-miR-767-3p, hsa-miR-153,
hsa-miR-31, hsa-miR-222, and two protective miRNAs:
hsa-miR-654 and hsa-miR-422b) were found to be sig-
nificantly correlated with clinical outcomes (p<0.05).
The risk score was calculated based on the expression of
these genes and was obtained in order to predict patient
survival. A total of 120 samples were divided into a
high-risk group (n = 60) and a low-risk group (n = 60)
according to their risk score. The heatmap shows that,
protective miRNAs exhibit high expression in low-risk
group, while the risky miRNAs have high expression in
high-risk group (Figure 1A). As shown in Figure 2A,
the patients in the high-risk group suffered obvious
worse overall survival than those in the low-risk group
(P < 0.0001).
Figure 1 (See legend on next page.)
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Figure 1 Analysis of the microRNA (miRNA) signature risk score is illustrated for the five subtypes of GBM. (A) Classical subtype;
(B) Neural subtype; (C) Mesenchymal subtype; (D) Proneural-G-CIMP subtype; (E) Proneural-non G-CIMP subtype. (Top) Patient survival status and
duration; (Middle) miRNA signature risk score distribution; (Bottom) heat map of ten miRNA expression profiles of patients with glioblastoma
multiforme. The rows represent risky and protective miRNAs, and the columns represent patients. The vertical line represents the miRNA signature
cutoff dividing patients into low-risk and high-risk groups.
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NAs (one risky miRNAs: hsa-miR-222 and seven protective
miRNAs: hsa-miR-422a, hsa-miR-662, hsa-miR-566, hsa-
miR-24, hsa-miR-370, hsa-miR-492, hsa-miR-629) as signa-
ture genes for predicting the patient outcomes (p<0.015)
(Figure 1B). Our result revealed that the prognoses of pa-
tients belonging to the high-risk group (n = 36) were worse
than those of the low-risk group (n = 37) (Figure 2B).Figure 2 Kaplan–Meier estimates of the overall survival of patients in
miRNAs. (A) Classical subtype; (B) Neural subtype; (C) Mesenchymal subty
P-values < 0.05 was considered significant.A total of 5 miRNAs (four risky miRNAs: miR-373,
miR-296, miR-191, miR-602; one protective miRNA:
miR-223) were selected to identify the overall survival of
patients in Mesenchymal subtype GBM (Figure 1C).
Compared with the high-risk group, the low-risk group
exhibited a better prognosis (p<0.001) (Figure 2C).
As for Proneural-G-CIMP and Proneural-non G-
CIMP subtype GBM, three (one risky miRNAs: hsa-miR-each subtype of glioblastoma multiforme based on significant
pe; (D) Proneural-G-CIMP subtype; (E) Proneural-non G-CIMP subtype.
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miR-195) and ten miRNAs (four risky miRNAs: hsa-
miR-335, hsa-miR-34a, hsa-miR-581, hsa-miR-21 and six
protective miRNAs: hsa-miR-361, hsa-miR-145, hsa-
miR-143, hsa-miR-378, hsa-miR-182, hsa-miR-183) were
filtered for intrinsic prognostic analysis, respectively
(Figure 1D-E). In both subtypes, the patients in the
high-risk group exhibited shorter survival than patients
in the low-risk group, as shown in Figure 2D-E.
Validation of the prognostic value of the miRNA
signatures of mesenchymal subtype in an independent
cohort
The prognostic miRNA signature for the Mesenchymal
subtype was further validated in an independent cohort
containing 41 Mesenchymal pGBM samples from CGGA.
The expression levels of the five prognostic miRNAs (hsa-
miR-373, hsa-miR-296, hsa-miR-191, hsa-miR-602 and
hsa-miR-223) in the Mesenchymal subtype were analyzed
by qRT-PCR in the independent cohort. The risk-score in
each sample of validation cohort were calculated accord-
ing the above formula. Furthermore, patients with Mesen-
chymal subtype GBM were divided into two groups based
on their risk-scores. Similar results were obtained: the
low-risk group exhibited extended survival, whereas the
high-risk group exhibited shorter survival (Figure 3).
Discussion
Glioblastoma multiforme (GBM) is the most malignant
type of glioma. People who suffer from GBM exhibit
poor prognosis. Survival ranges from one week to longer
than three years, but most patients only survive approxi-
mately one year [13,14]. Decades of effort in clinical
treatment have not satisfactorily improved prognosis. ToFigure 3 Validation of the prognostic value of gene signatures
of the Mesenchymal subtype in an independent cohort by
Kaplan–Meier analysis.improve the situation, researchers have begun to use
molecular biological technologies to identify new ap-
proaches. Data on some important biomarkers in the
progression of GBM, such as loss of heterozygosity
(LOH) 10q, EGFR amplification, TP53 mutations, and
PTEN mutations, have been collected and considered as
certain gene targets [15,16]. To improve target efficiency,
classifications of GBM have been established based on
different gene signatures, including mRNA expression
[17,18], microRNA expression, and methylation [19,20].
The generally accepted gene expression-based molecular
classification by Phillips, H.S. et al. divides GBM into the
Proneural, Neural, Classical and Mesenchymal subtypes
[21]. Further studies divide the Proneural subtype of
GBM into Proneural-G-CIMP and Proneural-non-G-
CIMP subtypes based on the CPG Island methylator
phenotype [22,23].
However, due to the complex mechanism of develop-
ment and progression of GBM and the diversity of gene
mutation, prognoses vary in samples of each subtype.
The isocitrate dehydrogenase 1 (IDH1) mutation was re-
ported to be a biomarker in the prediction of clinical
outcomes for patients with GBM, and patients with
IDH1 mutations exhibit better outcome than those with
wild-type IDH1 in gliomas. However, the genomic alter-
ation was frequent in grade II and grade III glial tumors
but rare in primary glioblastoma (pGBM) [24,25]. An-
other prognostic biomarker, MGMT DNA methylation,
was reported by Brennan CW et al. [6]. Only in classical
subtype GBM, MGMT DNA methylation may be a pre-
dictive biomarker for treatment response. Patients with
MGMT DNA methylation exhibit significantly better out-
comes than atients with MGMT DNA unmethylation.
However, the other four subtypes, Proneural-G-CIMP,
Proneural-non G-CIMP, Neural, and Mesenchymal, exhibit
no significant difference in clinical prognosis based on the
MGMT DNA methylation biomarker. This prompted us
to identify molecular prognostic markers that exist in
all subtypes of GBM. In present study, we choose miR-
NAs as predictive biomarkers for intrinsic prognostic
stratification. By using permutation tests and Cox regres-
sion analyses, significant genes were filtered and risk
scores were calculated to help us divide patients into low-
and high-risk groups. Our results revealed that in all five
subtypes, patients belonging to the low-risk groups had
significant longer overall survival than those in the
high-risk group. Additionally, we validated the results
in an independent database (CGGA) and obtained simi-
lar results. Although significant miRNAs were selected
as predictive biomarkers for each subtype, there are
many other factors, including age, sex, race and differ-
ent treatment strategies, which may affect clinical out-
comes and should also be taken into consideration in
the treatment of glioblastoma.
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considered biomarkers for prognosis stratification in
each subtype of glioblastoma, which could provide a
novel approach in the evaluation of the prognosis and
selection of the gene therapy targets.
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